{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:44:53Z","timestamp":1758041093581,"version":"3.44.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2023JJ40975"],"award-info":[{"award-number":["2023JJ40975"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Central South University Innovation-Driven Research Programme","award":["2023CXQD075"],"award-info":[{"award-number":["2023CXQD075"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-18515-8","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T10:47:38Z","timestamp":1757587658000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of CD159A as a prognostic and immune biomarker in kidney renal clear cell carcinoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Jing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyun","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunlin","family":"Ou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"18515_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L. et al. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"18515_CR2","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.18632\/aging.204607","volume":"15","author":"X Yang","year":"2023","unstructured":"Yang, X. et al. Expression profile and prognostic values of GATA family members in kidney renal clear cell carcinoma. Aging 15, 2170\u20132188 (2023).","journal-title":"Aging"},{"key":"18515_CR3","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"18515_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","volume":"84","author":"M Roupr\u00eat","year":"2023","unstructured":"Roupr\u00eat, M. et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 update. Eur. Urol. 84, 49\u201364 (2023).","journal-title":"Eur. Urol."},{"key":"18515_CR5","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40364-023-00530-4","volume":"11","author":"J Zhang","year":"2023","unstructured":"Zhang, J. et al. Novel role of immune-related non-coding RNAs as potential biomarkers regulating tumour immunoresponse via MICA\/NKG2D pathway. Biomark. Res. 11, 86 (2023).","journal-title":"Biomark. Res."},{"key":"18515_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12985-020-01308-y","volume":"17","author":"J Zhang","year":"2020","unstructured":"Zhang, J. et al. Long noncoding RNAs involvement in Epstein\u2013Barr virus infection and tumorigenesis. Virol. J. 17, 51 (2020).","journal-title":"Virol. J."},{"key":"18515_CR7","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.3390\/cancers14225657","volume":"14","author":"J Xiao","year":"2022","unstructured":"Xiao, J. et al. Natural killer cells: A promising kit in the adoptive cell therapy toolbox. Cancers 14, 3533 (2022).","journal-title":"Cancers"},{"key":"18515_CR8","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1002\/jmv.25516","volume":"91","author":"J Zhang","year":"2019","unstructured":"Zhang, J. et al. Differential expression profiling of lncRNAs related to Epstein\u2013Barr virus infection in the epithelial cells. J. Med. Virol. 91, 1845\u20131855 (2019).","journal-title":"J. Med. Virol."},{"key":"18515_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41571-019-0182-8","volume":"16","author":"BC Creelan","year":"2019","unstructured":"Creelan, B. C. & Antonia, S. J. The NKG2A immune checkpoint\u2014a new direction in cancer immunotherapy. Nat. Rev. Clin. Oncol. 16, 277\u2013278 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"18515_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.795372","volume":"12","author":"L Peng","year":"2021","unstructured":"Peng, L. et al. Emerging role of cancer-associated fibroblasts-derived exosomes in tumorigenesis. Front. Immunol. 12, 795372 (2021).","journal-title":"Front. Immunol."},{"key":"18515_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.888093","volume":"9","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. The Hippo pathway effector transcriptional co-activator with PDZ-binding motif correlates with clinical prognosis and immune infiltration in colorectal cancer. Front. Med. 9, 888093 (2022).","journal-title":"Front. Med."},{"key":"18515_CR12","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1158\/1078-0432.CCR-19-2095","volume":"26","author":"L Borst","year":"2020","unstructured":"Borst, L. et al. The NKG2A-HLA-E axis as a novel checkpoint in the tumor microenvironment. Clin. Cancer Res. 26, 5549\u20135556 (2020).","journal-title":"Clin. Cancer Res."},{"key":"18515_CR13","doi-asserted-by":"publisher","first-page":"1231916","DOI":"10.3389\/fimmu.2023.1231916","volume":"14","author":"A Mac Donald","year":"2023","unstructured":"Mac Donald, A. et al. KLRC1 knockout overcomes HLA-E-mediated inhibition and improves NK cell antitumor activity against solid tumors. Front. Immunol. 14, 1231916 (2023).","journal-title":"Front. Immunol."},{"key":"18515_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110503","volume":"38","author":"Q Hammer","year":"2022","unstructured":"Hammer, Q. et al. SARS-CoV-2 Nsp13 encodes for an HLA-E-stabilizing peptide that abrogates inhibition of NKG2A-expressing NK cells. Cell Rep. 38, 110503 (2022).","journal-title":"Cell Rep."},{"key":"18515_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41587-021-01037-9","volume":"40","author":"J Loske","year":"2022","unstructured":"Loske, J. et al. Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children. Nat. Biotechnol. 40, 319\u2013324 (2022).","journal-title":"Nat. Biotechnol."},{"key":"18515_CR16","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/s41467-019-09212-y","volume":"10","author":"C Zhang","year":"2019","unstructured":"Zhang, C. et al. NKG2A is a NK cell exhaustion checkpoint for HCV persistence. Nat. Commun. 10, 1507 (2019).","journal-title":"Nat. Commun."},{"key":"18515_CR17","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s43018-021-00316-3","volume":"3","author":"Y Xie","year":"2022","unstructured":"Xie, Y. et al. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes. Nat. Cancer 3, 188\u2013202 (2022).","journal-title":"Nat. Cancer"},{"key":"18515_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1264562","volume":"6","author":"C Sun","year":"2017","unstructured":"Sun, C. et al. High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer. Oncoimmunology 6, e1264562 (2017).","journal-title":"Oncoimmunology"},{"key":"18515_CR19","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.ccell.2022.08.005","volume":"40","author":"S Salom\u00e9","year":"2022","unstructured":"Salom\u00e9, S. et al. NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. Cancer Cell 40, 1027\u20131043 (2022).","journal-title":"Cancer Cell"},{"key":"18515_CR20","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/ijc.33859","volume":"150","author":"L Borst","year":"2022","unstructured":"Borst, L. et al. NKG2A is a late immune checkpoint on CD8 T cells and marks repeated stimulation and cell division. Int. J. Cancer 150, 688\u2013704 (2022).","journal-title":"Int. J. Cancer"},{"key":"18515_CR21","doi-asserted-by":"publisher","first-page":"6749","DOI":"10.1158\/1078-0432.CCR-21-0972","volume":"27","author":"S Terry","year":"2021","unstructured":"Terry, S. et al. Association of AXL and PD-L1 expression with clinical outcomes in patients with advanced renal cell carcinoma treated with PD-1 blockade. Clin. Cancer Res. 27, 6749\u20136760 (2021).","journal-title":"Clin. Cancer Res."},{"key":"18515_CR22","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","volume":"175","author":"P Andr\u00e9","year":"2018","unstructured":"Andr\u00e9, P. et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell 175, 1731\u20131743 (2018).","journal-title":"Cell"},{"key":"18515_CR23","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.cell.2018.10.028","volume":"175","author":"N van Montfoort","year":"2018","unstructured":"van Montfoort, N. et al. NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines. Cell 175, 1744\u20131755 (2018).","journal-title":"Cell"},{"key":"18515_CR24","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1172\/JCI123955","volume":"129","author":"T Kamiya","year":"2019","unstructured":"Kamiya, T. et al. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. J. Clin. Invest. 129, 2094\u20132106 (2019).","journal-title":"J. Clin. Invest."},{"key":"18515_CR25","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1126\/science.aan5951","volume":"359","author":"D Miao","year":"2018","unstructured":"Miao, D. et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science 359, 801\u2013806 (2018).","journal-title":"Science"},{"key":"18515_CR26","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.ccell.2021.02.013","volume":"39","author":"DA Braun","year":"2021","unstructured":"Braun, D. A. et al. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell 39, 632\u2013648 (2021).","journal-title":"Cancer Cell"},{"key":"18515_CR27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.celrep.2018.03.075","volume":"23","author":"CJ Ricketts","year":"2018","unstructured":"Ricketts, C. J. et al. The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 23, 313\u2013326 (2018).","journal-title":"Cell Rep."},{"key":"18515_CR28","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"18515_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007202","volume":"11","author":"BA Hussein","year":"2023","unstructured":"Hussein, B. A. et al. NKG2A gene variant predicts outcome of immunotherapy in AML and modulates the repertoire and function of NK cells. J. Immunother. Cancer 11, e008411 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"18515_CR30","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1158\/2159-8290.CD-23-0313","volume":"13","author":"BC Taylor","year":"2023","unstructured":"Taylor, B. C. et al. NKG2A is a therapeutic vulnerability in immunotherapy resistant MHC-I heterogeneous triple negative breast cancer. Cancer Discov. 13, 876\u2013887 (2023).","journal-title":"Cancer Discov."},{"key":"18515_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.886440","volume":"12","author":"M Gemelli","year":"2022","unstructured":"Gemelli, M. et al. Overcoming resistance to checkpoint inhibitors: Natural killer cells in non-small cell lung cancer. Front. Oncol. 12, 886440 (2022).","journal-title":"Front. Oncol."},{"key":"18515_CR32","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1158\/2326-6066.CIR-18-0733","volume":"7","author":"X Zhuang","year":"2019","unstructured":"Zhuang, X. & Long, E. O. CD28 homolog is a strong activator of natural killer cells for lysis of B7H7+ tumor cells. Cancer Immunol. Res. 7, 939\u2013951 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"18515_CR33","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s00262-022-03299-x","volume":"72","author":"NA Beelen","year":"2023","unstructured":"Beelen, N. A. et al. Inhibitory receptors for HLA class I as immune checkpoints for natural killer cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Cancer Immunol. Immunother. 72, 797\u2013804 (2023).","journal-title":"Cancer Immunol. Immunother."},{"key":"18515_CR34","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s40364-023-00538-w","volume":"11","author":"M Zhou","year":"2023","unstructured":"Zhou, M. et al. Exosome derived from tumor-associated macrophages: biogenesis, functions, and therapeutic implications in human cancers. Biomark. Res. 11, 100 (2023).","journal-title":"Biomark. Res."},{"key":"18515_CR35","doi-asserted-by":"publisher","first-page":"2081415","DOI":"10.1080\/2162402X.2022.2081415","volume":"11","author":"T Bexte","year":"2022","unstructured":"Bexte, T. et al. CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma. Oncoimmunology 11, 2081415 (2022).","journal-title":"Oncoimmunology"},{"key":"18515_CR36","doi-asserted-by":"publisher","first-page":"2046931","DOI":"10.1080\/2162402X.2022.2046931","volume":"11","author":"K Ducoin","year":"2022","unstructured":"Ducoin, K. et al. Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer. Oncoimmunology 11, 2046931 (2022).","journal-title":"Oncoimmunology"},{"key":"18515_CR37","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1186\/s12967-021-03203-8","volume":"19","author":"HY Na","year":"2021","unstructured":"Na, H. Y. et al. Prognostic significance of natural killer cell-associated markers in gastric cancer: quantitative analysis using multiplex immunohistochemistry. J. Transl. Med. 19, 529 (2021).","journal-title":"J. Transl. Med."},{"key":"18515_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107764","volume":"96","author":"Q Li","year":"2021","unstructured":"Li, Q. et al. Natural killer cell exhaustion in lung cancer. Int. Immunopharmacol. 96, 107764 (2021).","journal-title":"Int. Immunopharmacol."},{"key":"18515_CR39","doi-asserted-by":"publisher","first-page":"6172","DOI":"10.1074\/jbc.RA118.006281","volume":"294","author":"M Li","year":"2019","unstructured":"Li, M. et al. Zinc-finger protein YY1 suppresses tumor growth of human nasopharyngeal carcinoma by inactivating c-Myc-mediated microRNA-141 transcription. J. Biol. Chem. 294, 6172\u20136187 (2019).","journal-title":"J. Biol. Chem."},{"key":"18515_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106098","volume":"9","author":"W Wang","year":"2014","unstructured":"Wang, W. et al. Activation of Akt\/mTOR pathway is associated with poor prognosis of nasopharyngeal carcinoma. PLoS ONE 9, e106098 (2014).","journal-title":"PLoS ONE"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18515-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18515-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18515-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T10:47:40Z","timestamp":1757587660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18515-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["18515"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-18515-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,9,11]]},"assertion":[{"value":"22 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This retrospective study was carried out using the opt-out method for the case series of our hospital. We have confirmed that all experiments were conducted in accordance with the relevant guidelines and regulations. This study was approved by the Ethics Committee of Xiangya Hospital (Approval No. 202401013) and was conducted in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was waived by our Institutional Review Board (Medical Ethics Committee of Xiangya Hospital, Central South University) because of the retrospective nature of our study. Research still conducts to comply with ethical norms.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"32410"}}